Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
145.3 USD | -1.99% | 0.00% | -6.76% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an enterprise value anticipated at 3.85 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.76% | 348B | - | ||
+40.50% | 731B | C+ | ||
+31.34% | 586B | B | ||
+16.89% | 319B | B- | ||
+0.35% | 273B | C+ | ||
+13.47% | 235B | B+ | ||
-6.63% | 203B | A+ | ||
+7.49% | 202B | B- | ||
+4.20% | 159B | C+ | ||
-2.90% | 158B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson